FibroGen Inc (NASDAQ:FGEN) price on Friday, April 11, rose 6.78% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.28.
A look at the stock’s price movement, the close in the last trading session was $0.26, moving within a range at $0.26 and $0.2818. The beta value (5-Year monthly) was 0.878. Turning to its 52-week performance, $1.74 and $0.18 were the 52-week high and 52-week low respectively. Overall, FGEN moved -35.10% over the past month.
FibroGen Inc’s market cap currently stands at around $27.98 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-16.
Analysts have a consensus estimate of 2M for the company’s revenue for the quarter, with a low and high estimate of 2M and 2M respectively. The average forecast suggests down to a -96.42% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 96.65M, representing a -52.46% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that FGEN is a 100% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend FGEN as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
FGEN’s current price about -12.16% and -33.18% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 38.41, while 7-day volatility ratio is 12.45% and 12.29% in the 30-day chart. Further, FibroGen Inc (FGEN) has a beta value of 0.93, and an average true range (ATR) of 0.04. Analysts have given the company’s stock an average 52-week price target of $28, forecast between a low of $28 and high of $28. Looking at the price targets, the low is -9900.0% off current price level while to achieve the yearly target high, price needs to move -9900.0%. Nonetheless, investors will most likely welcome a -9900.0% jump to $28 which is the analysts’ median price.
If we refocus on FibroGen Inc (NASDAQ:FGEN), historical trading data shows that trading volumes averaged 0.95 over the past 10 days and 3.39 million over the past 3 months. The company’s latest data on shares outstanding shows there are 100.92 million shares.
The 6.90% of FibroGen Inc’s shares are in the hands of company insiders while institutional holders own 36.01% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.98 million on 2025-03-14, giving us a short ratio of 0.61. The data shows that as of 2025-03-14 short interest in FibroGen Inc (FGEN) stood at 580.0000200000001 of shares outstanding, with shares short rising to 2.95 million registered in 2025-02-14. Current price change has pushed the stock -47.65% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the FGEN stock continues to rise going into the next quarter.
